Patents Examined by Brian E McDowell
-
Patent number: 11780845Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.Type: GrantFiled: January 31, 2023Date of Patent: October 10, 2023Assignees: Relay Therapeutics, Inc., D.E. Shaw Research, LLCInventors: Bakary-Barry Touré, Heike Schoenherr, Fabrizio Giordanetto, Demetri T. Moustakas, Brandi M. Hudson
-
Patent number: 11773083Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.Type: GrantFiled: December 6, 2022Date of Patent: October 3, 2023Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBHInventors: Polina Lapido, Inbal Shumacher, Ofir Shaul
-
Patent number: 11773078Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.Type: GrantFiled: May 10, 2019Date of Patent: October 3, 2023Assignee: Glaxosmithkline Intellectual Property Development LimitedInventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Huiping Amy Guan, Yan Hu, Aaron Bayne Miller, Donghui Qin, Chengde Wu, Zhiliu Zhang, Xiaojuan Lin
-
Patent number: 11773099Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. The fused heteroaryl compounds of the disclosure are represented by Formula (I): wherein X, Y, Z, A, R1 and R2 are as defined in the specification. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.Type: GrantFiled: May 28, 2020Date of Patent: October 3, 2023Assignee: Praxis Precision Medicines, Inc.Inventors: Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
-
Patent number: 11760745Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.Type: GrantFiled: February 11, 2021Date of Patent: September 19, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Matthias Eckhardt, Maude Giroud, Elke Langkopf, Camilla Mayer, Holger Wagner, Dieter Wiedenmayer
-
Patent number: 11760722Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.Type: GrantFiled: June 10, 2022Date of Patent: September 19, 2023Assignee: ASCLETIS BIOSCIENCE CO., LTD.Inventors: Bailing Yang, Bin Liang, Yang Lai, Jinzi J. Wu
-
Patent number: 11753400Abstract: The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent; is a single bond or a double bond; each of X, Y, and Z, independently, is aryl, heteroaryl, aralkyl, H, or absent; each of L1 and L2, independently, is a moiety selected from O, CH2, C?O, C2-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, —((CH2)n—W)—, wherein n=0, 1, 2, 3, 4, or 5, and W is O or S, or absent; and when L2 is absent, Z is aryl or heteroaryl fused with BC. Also provided in the present invention is a method for inhibiting, treating and/or reducing the risk of a neuropsychiatric disorder, comprising administering a subject in need a composition comprising a compound of Formula (I).Type: GrantFiled: October 18, 2018Date of Patent: September 12, 2023Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Yuan-Ting Hsieh
-
Patent number: 11753397Abstract: The invention provides cereblon binders of Formulas: or pharmaceutically acceptable salts thereof, for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications to treat medical disorders including, but not limited to cancer.Type: GrantFiled: September 24, 2020Date of Patent: September 12, 2023Assignee: C4 Therapeutics, Inc.Inventors: James A. Henderson, Gesine Kerstin Veits, Minsheng He, Christopher G. Nasveschuk, Andrew J. Phillips, Andrew Charles Good
-
Patent number: 11746103Abstract: Provided herein are compounds (e.g., compounds of Formulae (I), (II), (III) and (IV), or of Table 1 or Table 4), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and kits comprising the same. The compounds provided herein are activin receptor-like kinase (e.g., ALK-5) inhibitors and are, therefore, useful, for example, for treating and/or preventing diseases (e.g., proliferative diseases, such as cancer) in a subject, inhibiting tumor growth in a subject, or inhibiting the activity of an activin receptor-like kinase (e.g., ALK-5) in vitro or in vivo. Also provided herein are methods and synthetic intermediates useful in the preparation of compounds described herein.Type: GrantFiled: April 29, 2022Date of Patent: September 5, 2023Assignee: Sumitomo Pharma Oncology, Inc.Inventors: Bettina Franz, Adam Siddiqui-Jain, Steven L. Warner, Siva Reddy Basireddy, Srinivas Padakanti, Naresh Kumar
-
Patent number: 11739074Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.Type: GrantFiled: November 4, 2020Date of Patent: August 29, 2023Assignee: Revolution Medicines, Inc.Inventors: James Aggen, G. Leslie Burnett, Jennifer Pitzen, Adrian L. Gill, Elena S. Koltun, James Cregg, Andreas Buckl, Anne V. Edwards, John E. Knox
-
Patent number: 11724982Abstract: The present invention provides a process of producing a trifluoromcthoxylated aryl or trifluoromothoxylated heteroaryl having the structure: wherein A is an aryl or heteroaryl, each with or without substitution; and R1 is —H, -(alkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(alkylaryl), -(alkylheteroaryl), —NH-(alkyl), —N(alkyl)2, —NH-(alkenyl), —NH-(alkynyl) —NH-(aryl), —NH-(heteroaryl), —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(aryl), —O-(heteroaryl), —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), or —S-(heteroaryl), comprising: (a) reacting a compound having the structure: with a trifluoromethylating agent in the presence of a base in a first suitable solvent under conditions to produce a compound having the structure: and (b) maintaining the compound produced in step (a) in a second suitable solvent under conditions sufficient to produce the trifluoromethoxylated aryl or trifluormethoxylated heteroaryl having the structure:Type: GrantFiled: May 6, 2020Date of Patent: August 15, 2023Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Ming-Yu Ngai, Katarzyna N. Hojczyk
-
Patent number: 11713307Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: October 15, 2020Date of Patent: August 1, 2023Assignee: CHEMOCENTRYX, INC.Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Darren J. McMurtrie, Ryan J. Scamp, Ju Yang, Yibin Zeng, Penglie Zhang
-
Patent number: 11708372Abstract: Described herein are crystalline composition comprising a Corticotropin-releasing hormone receptor 1 (CRF1) antagonist, such as Compound 1: methods of making such crystalline composition, pharmaceutical compositions and medicaments comprising such crystalline composition, and methods of using such crystalline composition in the treatment of conditions, diseases, or disorders that would benefit from modulation of CRF.Type: GrantFiled: April 13, 2022Date of Patent: July 25, 2023Assignee: SPRUCE BIOSCIENCES, INC.Inventors: Dasharatha Reddy, Ashokraj Rajagopal, Lu Wang, Christopher Barnes
-
Patent number: 11708334Abstract: The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging; wherein the inhibitors of NLRP3 inflammasomes are compounds of Formula VII: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 9, 2022Date of Patent: July 25, 2023Assignee: BIOAGE LABS, INC.Inventors: George Hartman, Paul Humphries, Kevin Edward Leif Wilhelmsen
-
Patent number: 11708353Abstract: The present application provides compounds, such as compounds of Formula Ia, which are inhibitors of aminoacyl tRNA-synthetase (e.g., prolyl-tRNA-synthetase), and which are useful for treating disorders associated with aminoacyl tRNA-synthetase activity and/or expression. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also provided.Type: GrantFiled: June 10, 2019Date of Patent: July 25, 2023Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: Ralph Mazitschek, Sofia A. Santos, Mark A. Tye, N. Connor Payne, Dyann F. Wirth
-
Patent number: 11707462Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.Type: GrantFiled: August 29, 2022Date of Patent: July 25, 2023Assignee: BOUNDLESS BIO, INC.Inventors: Anthony B. Pinkerton, Stephen Todd Meyer, Jacques Mauger, Yen Pham Hong Truong, Rachelle Janette Elsdon
-
Patent number: 11702391Abstract: The present disclosure relates to compounds of Formula I: that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.Type: GrantFiled: March 23, 2022Date of Patent: July 18, 2023Assignees: BIOAGE LABS, INC., HITGEN, INC.Inventors: George Hartman, Xu He, Jia Du, Lifang Zhang, Paul Humphries, Kevin Edward Leif Wilhelmsen
-
Patent number: 11691969Abstract: The present invention relates to pyridazinones and related compounds having Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PARP7 and are useful in the treatment of cancer.Type: GrantFiled: October 29, 2020Date of Patent: July 4, 2023Assignee: Ribon Therapeutics, Inc.Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
-
Patent number: 11685727Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.Type: GrantFiled: December 18, 2020Date of Patent: June 27, 2023Assignee: NUEVOLUTION A/SInventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi, Montserrat Erra Solà, Lorena Taboada Martínez, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Lluís Miquel Pagès Santacana
-
Patent number: 11680056Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.Type: GrantFiled: July 19, 2022Date of Patent: June 20, 2023Assignee: XINTHERA, INC.Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor, Robert L. Hoffman